	US 11,891,428 B2
	Cellular fibronectin compositions
Spencer Alford, Newark, CA (US); and Audrey Smith, Menlo Park, CA (US)
Assigned to COMBANGIO, INC., Menlo Park, CA (US)
Filed by COMBANGIO, INC., Menlo Park, CA (US)
Filed on Jul. 8, 2022, as Appl. No. 17/860,954.
Application 17/860,954 is a continuation of application No. 17/856,944, filed on Jul. 1, 2022.
Claims priority of provisional application 63/217,952, filed on Jul. 2, 2021.
Claims priority of provisional application 63/235,605, filed on Aug. 20, 2021.
Prior Publication US 2023/0002476 A1, Jan. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/18 (2006.01); A61K 38/17 (2006.01); A61K 38/36 (2006.01); C07K 14/78 (2006.01); A61K 38/39 (2006.01); A61P 27/02 (2006.01); A61K 9/16 (2006.01); A61K 35/28 (2015.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); C07K 14/475 (2006.01); C12N 5/0775 (2010.01)

CPC C07K 14/78 (2013.01) [A61K 9/1623 (2013.01); A61K 35/28 (2013.01); A61K 38/177 (2013.01); A61K 38/1709 (2013.01); A61K 38/1833 (2013.01); A61K 38/1858 (2013.01); A61K 38/1866 (2013.01); A61K 38/36 (2013.01); A61K 38/39 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); A61P 27/02 (2018.01); C07K 14/475 (2013.01); C12N 5/0663 (2013.01); C12N 5/0668 (2013.01)]

30 Claims

1. A composition comprising fibronectin (FN), wherein the FN is mesenchymal stem cell (MSC)-derived FN, wherein the MSCs are derived from bone marrow, wherein the FN is soluble, and wherein the composition does not comprise one or more components selected from the group consisting of: xenobiotic components; Phenol red; peptides and biomolecules <3 kDa; antibiotics; protein aggregates; cells; cell debris; hormones; and L-glutamine.